News stories about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.7156279209 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
AMAG has been the topic of a number of recent research reports. Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Monday, October 23rd. Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Cantor Fitzgerald restated a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Jefferies Group reaffirmed a “buy” rating and set a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. Finally, Morgan Stanley dropped their price target on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Fourteen equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $21.58.
AMAG Pharmaceuticals (AMAG) traded down $0.35 during trading hours on Wednesday, hitting $14.40. The company had a trading volume of 1,055,500 shares, compared to its average volume of 865,283. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $508.15, a P/E ratio of -2.37 and a beta of 0.79. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $25.20.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/10/amag-pharmaceuticals-amag-earning-somewhat-favorable-media-coverage-accern-reports.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.